Progressive Myoclonic Epilepsy

Gene: CLN5

Green List (high evidence)

CLN5 (CLN5, intracellular trafficking protein)
EnsemblGeneIds (GRCh38): ENSG00000102805
EnsemblGeneIds (GRCh37): ENSG00000102805
OMIM: 608102, ClinGen, DECIPHER
CLN5 is in 13 panels

2 reviews

Zornitza Stark (Victorian Clinical Genetics Services)

Green List (high evidence)

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Ceroid lipofuscinosis, neuronal, 5, MIM# 256731

Noor Al-Ali (Other)

Green List (high evidence)

Pathogenic variants in this gene cause a disease called neuronal ceroid lipofuscinosis 5 (CLN5-NCL), a rare neurodegenerative disorder that predominantly affects the Finnish population. The underlying pathogenesis is associated with the accumulation of lipopigment storage material within cells. The disease is characterized by symptoms including developmental delay, myoclonic epilepsy, ataxia, visual impairment, and cognitive decline. The age of onset can range from late infancy to the juvenile period, with varying rates of progression. Childhood-onset CLN5-NCL commonly manifests with myoclonic epilepsy that clinically overlaps with progressive myoclonic epilepsy. Therefore, the CLN5 gene can be considered associated with progressive myoclonic epilepsy.
Most pathogenic mutations, including nonsense mutations, frameshift insertions/deletions, and splice-site variants, lead to truncated or non-functional CLN5 protein.
Created: 19 Nov 2025, 11:47 p.m. | Last Modified: 19 Nov 2025, 11:47 p.m.
Panel Version: 0.22

Mode of inheritance
BIALLELIC, autosomal or pseudoautosomal

Phenotypes
Onset at 4 to 7 years; progressive vision loss; retinal degeneration; nystagmus; clumsiness; motor deterioration; developmental regression; ataxia; dysarthria; dysmetria; dysdiadochokinesis; seizures; myoclonus; intellectual disability; cognitive impairment; neurophysiologic abnormalities (EEG, VEP, SEP); characteristic findings on MRI; autofluorescent lipopigment in neurons; cerebellar atrophy (in one family); concentration difficulties; “fingerprint” profiles ultrastructurally; “curvilinear” profiles ultrastructurally; “rectilinear” profiles ultrastructurally.

Publications

Mode of pathogenicity
Loss-of-function variants (as defined in pop up message) DO NOT cause this phenotype - please provide details in the comments

History Filter Activity

21 Nov 2025, Gel status: 3

Entity classified by Genomics England curator

Zornitza Stark (Victorian Clinical Genetics Services)

Gene: cln5 has been classified as Green List (High Evidence).

21 Nov 2025, Gel status: 3

Set publications

Zornitza Stark (Victorian Clinical Genetics Services)

Publications for gene: CLN5 were set to

9 Jan 2020, Gel status: 3

Created, Added New Source, Set mode of inheritance, Set Phenotypes

Bryony Thompson (Royal Melbourne Hospital)

gene: CLN5 was added gene: CLN5 was added to Progressive Myoclonic Epilepsy_RMH. Sources: Expert Review Green,Royal Melbourne Hospital Mode of inheritance for gene: CLN5 was set to BIALLELIC, autosomal or pseudoautosomal Phenotypes for gene: CLN5 were set to Ceroid lipofuscinosis, neuronal, 5, MIM#256731